{"id":899,"date":"2011-06-29T09:44:45","date_gmt":"2011-06-29T13:44:45","guid":{"rendered":"http:\/\/jamie.workingagenda.com\/blog\/?p=899"},"modified":"2018-10-22T12:30:42","modified_gmt":"2018-10-22T16:30:42","slug":"nih-funded-grants-and-patents","status":"publish","type":"post","link":"https:\/\/jamie.workingagenda.com\/blog\/2011\/06\/29\/nih-funded-grants-and-patents\/","title":{"rendered":"NIH funded grants and patents for selected diseases or technologies"},"content":{"rendered":"<\/abbr>\n

(Update:<\/strong> Note that the NIH Report database key word searches report grants, and some patents are associated with more than one grant. This is true for all search terms listed below.<\/em><\/p>\n

As part of a larger research project involving the role of government funded research, I was doing some counts of grants and patents associated with those grants, using the NIH RePort database<\/a>. <\/p>\n

The counts reported below are from searches on June 29, 2011.<\/p>\n

Not surprisingly, if you have a disease, there are advantages to having one with a large patient population, and at least equal prevalence in high income countries.<\/p>\n

I have also calculated the ratio of the patents to the number of grants, expressed below as a percent, in parenthesis after the number of patents. The unweighted mean and median were 4.8 and 4.1 percent, with a range of 0 to 12.3 percent, and a standard deviation of 2.77 percent. The tendency for grant recipients to obtain patents does not seem to differ much between Type I, II or III diseases — a classification used by the World Health Organization to indicate how the global incidence of the disease relates to national incomes. <\/p>\n

Diseases<\/strong><\/p>\n

Type I<\/em><\/p>\n

NIH grants mentioning cancer: 248,057
\nPatents from NIH grants mentioning cancer: 7,665 (3.1%)<\/p>\n

NIH grants mentioning breast cancer: 45,338
\nPatents from NIH grants mentioning breast cancer: 1,905 (4.2%)<\/p>\n

NIH grants mentioning prostate cancer: 21,334
\nPatents from NIH grants mentioning prostate cancer: 1,106 (5.2%)<\/p>\n

NIH grants mentioning depression: 41,761
\nPatents from NIH grants mentioning depression: 883 (2.1%)<\/p>\n

NIH grants mentioning dementia: 20,031
\nPatents from NIH grants mentioning dementia: 712 (3.6%)<\/p>\n

NIH grants mentioning Alzheimer’s: 2,893
\nPatents from NIH grants mentioning Alzheimer’s: 357 (12.3%<\/p>\n

NIH grants mentioning asthma: 19,268
\nPatents from NIH grants mentioning asthma: 648 (3.4%)<\/p>\n

Type I orphan diseases<\/em><\/p>\n

NIH grants mentioning Progressive Supranuclear Palsy: 471
\nPatents from NIH grants mentioning Progressive Supranuclear Palsy: 15 (3.2%)<\/p>\n

NIH grants mentioning Fabry’s disease: 390
\nPatents from NIH grants mentioning Fabry’s disease: 43 (11.0%)<\/p>\n

NIH grants mentioning Turner syndrome: 592
\nPatents from NIH grants mentioning Turner syndrome: 52 (8.8%)<\/p>\n

Type II\/ MDG<\/em><\/p>\n

NIH grants mentioning HIV: 93,651
\nPatents from NIH grants mentioning HIV: 2,209 (2.4%)<\/p>\n

NIH grants mentioning tuberculosis: 10,768
\nPatents from NIH grants mentioning tuberculosis: 366 (4.2%)<\/p>\n

NIH grants mentioning malaria: 6,905
\nPatents from NIH grants mentioning malaria: 293 (4.1%)<\/p>\n

Type III<\/em><\/p>\n

NIH grants mentioning leishmaniasis: 1,809
\nPatents from NIH grants mentioning leishmaniasis: 75 (4.1%)<\/p>\n

NIH grants mentioning Chagas: 1,256
\nPatents from NIH grants mentioning Chagas: 47 (3.7%)<\/p>\n

NIH grants mentioning cholera: 2,907
\nPatents from NIH grants mentioning cholera: 333 (11.5%)<\/p>\n

NIH grants mentioning Dengue: 1,694
\nPatents from NIH grants mentioning Dengue: 69 (4.1%)<\/p>\n

NIH grants mentioning Onchocerciasis: 245
\nPatents from NIH grants mentioning Onchocerciasis: 8 (3.3%)<\/p>\n

NIH grants mentioning schistosomiasis: 1,277
\nPatents from NIH grants mentioning schistosomiasis: 47 3.7%)<\/p>\n

Other areas of priority<\/em><\/p>\n

NIH grants mentioning Antibiotic resistance: 6,278
\nPatents from NIH grants mentioning Antibiotic resistance: 392 (6.2%)<\/p>\n

Technologies<\/strong><\/p>\n

NIH grants mentioning diagnostic: 70,006
\nPatents from NIH grants mentioning diagnostic: 3,598 (5.1%)<\/p>\n

NIH grants mentioning genomics: 42,187
\nPatents from NIH grants mentioning genomics: 1,864 (4.4%)<\/p>\n

NIH grants mentioning gene sequence: 104,873
\nPatents from NIH grants mentioning gene sequence: 7,293 (7.0%)<\/p>\n

NIH grants mentioning genetic disorder: 74,602
\nPatents from NIH grants mentioning genetic disorder: 3,332 (4.5%)<\/p>\n

Other key words<\/strong><\/p>\n

NIH grants mentioning poverty: 4,837
\nPatents from NIH grants mentioning poverty: 87 (1.8%)<\/p>\n

NIH grants mentioning contraception: 6,202
\nPatents from NIH grants mentioning contraception: 350 (5.6%)<\/p>\n

NIH grants mentioning male circumcision: 197
\nPatents from NIH grants mentioning male circumcision: 9 (4.6%)<\/p>\n

NIH grants mentioning female circumcision: 85
\nPatents from NIH grants mentioning female circumcision: 0 (0%)<\/p>\n

NIH grants mentioning bioterrorism: 5,176
\nPatents from NIH grants mentioning bioterrorism: 189 (3.7%)<\/p>\n

NIH grants mentioning Africa: 8,215
\nPatents from NIH grants mentioning Africa: 228 (2.8%)<\/p>\n","protected":false},"excerpt":{"rendered":"

(Update: Note that the NIH Report database key word searches report grants, and some patents are associated with more than one grant. This is true for all search terms listed below. As part of a larger research project involving the role of government funded research, I was doing some counts of grants and patents associated […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[],"_links":{"self":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/899"}],"collection":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/comments?post=899"}],"version-history":[{"count":49,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/899\/revisions"}],"predecessor-version":[{"id":1496,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/posts\/899\/revisions\/1496"}],"wp:attachment":[{"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/media?parent=899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/categories?post=899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jamie.workingagenda.com\/blog\/wp-json\/wp\/v2\/tags?post=899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}